Syneron(TM) Unveils New eMatrix(TM) Clinical Data on Fractional Treatments for Darker Skin Types at American Academy of Dermatology Annual Meeting
Syneron Hosts Physician eLounge at AAD Conference

IRVINE, CA and YOKNEAM, ISRAEL -- (Marketwire) -- 03/04/2009 -- Syneron™ Medical Ltd. (NASDAQ: ELOS), http://www.syneron.com, an innovator in the development, marketing and sales of elos™ combined-energy medical aesthetic devices, will reveal new clinical data proving the powerful eMatrix skin resurfacing device's efficacy on darker skin types at this week's American Academy of Dermatology 67th Annual Meeting in San Francisco. The only fractional device capable of safely treating patients with skin of color (skin types V and VI on the Fitzpatrick skin classification scale), eMatrix opens the in-demand fractional ablative treatment market to a larger patient base.

Named first prize winner in the device category for its industrial design by the Israel Ministry of Industry, Trade & Labor, the stylish and functional eMatrix utilizes Matrix RF™ technology, http://www.matrixskin.com, the world's first RF-only fractional technology for ablation and skin resurfacing. Clinical studies currently in process using eMatrix's Matrix RF technology reveal the unique ability to treat skin of color due to the RF-based energy applied to the skin. Launched in December 2008, results of Matrix RF treatments with the eMatrix device include skin rejuvenation, wrinkle reduction and skin tightening.

More: Go to full press release, eMatrix Video, and AAD Premiere Party Invitation information...